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Purpose: To investigate the pattern of neuromelanin signal intensity 
loss within the substantia nigra pars compacta (SNpc), 
locus coeruleus, and ventral tegmental area in Parkinson 
disease (PD); the specific aims were (a) to study regional 
magnetic resonance (MR) quantifiable depigmentation 
in association with PD severity and (b) to investigate 
whether imaging- and platform-dependent signal intensity 
variations can be normalized.
Materials and 
Methods:
This prospective case-control study was approved by the 
local ethics committee and the research department of 
Nottingham University Hospitals. Written informed con-
sent was obtained from all participants before enrollment 
in the study. Sixty-nine participants (39 patients with 
PD and 30 control subjects) were investigated with neu-
romelanin-sensitive MR imaging by using two different 3-T 
platforms and three differing protocols. Neuromelanin-re-
lated volumes of the anterior and posterior SNpc, locus 
coeruleus, and ventral tegmental area were determined, 
and normalized neuromelanin volumes were assessed for 
protocol-dependent effects. Diagnostic test performance 
of normalized neuromelanin volume was investigated 
by using receiver operating characteristic analyses, and 
correlations with the Unified Parkinson’s Disease Rating 
Scale scores were tested.
Results: Reduction of normalized neuromelanin volume in PD was 
most pronounced in the posterior SNpc (median, 283%; 
P , .001), followed by the anterior SNpc (249%; P , 
.001) and the locus coeruleus (237%; P , .05). Nor-
malized neuromelanin volume loss of the posterior and 
whole SNpc allowed the best differentiation of patients 
with PD and control subjects (area under the receiver op-
erating characteristic curve, 0.92 and 0.88, respectively). 
Normalized neuromelanin volume of the anterior, poste-
rior, and whole SNpc correlated with Unified Parkinson’s 
Disease Rating Scale scores (r2 = 0.25, 0.22, and 0.28, 
respectively; all P , .05).
Conclusion: PD-induced neuromelanin loss can be quantified across 
imaging protocols and platforms by using appropriate ad-
justment. Depigmentation in PD follows a distinct spatial 
pattern, affords high diagnostic accuracy, and is associ-
ated with disease severity.
Published under a CC BY 4.0 license.
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ventral tegmental area (VTA), and the 
locus coeruleus (LC) (1). Anatomically, 
these nuclei can be readily appreciated 
macroscopically because of a pigment 
accumulated within the cells called neu-
romelanin (2). This protein polymer 
has a molecular structure similar to the 
skin pigment melanin and is a by-prod-
uct of catecholamine synthesis. It is 
deposited within the cells in an age-de-
pendent manner and is largely absent 
at birth, with accumulation throughout 
adult life (3,4). There is a PD-induced 
pathologic decline of SNpc, VTA, and 
LC neurons that contain neuromelanin, 
which results in pronounced depigmen-
tation (5,6).
Although the whole of the pars 
compacta is involved in PD-induced 
neurodegeneration, the dopaminergic 
cell loss is nonuniform across its subre-
gions. An area previously described as 
“ventrolateral” substantia nigra is pref-
erentially and most extensively affected 
(7). The degree of neuronal loss in 
the SNpc is correlated to PD severity, 
which confirms the potential of SNpc 
imaging in tracking disease progression 
(8,9). By exploiting the paramagnetic 
properties of neuromelanin, T1-weight-
ed “neuromelanin-sensitive” magnetic 
resonance (MR) imaging sequences 
have been developed to identify and 
characterize the SNpc and LC in vivo 
and demonstrate PD-induced signal in-
tensity loss (10,11). Neuromelanin-re-
lated MR imaging SNpc signal intensity 
increase and corresponding loss in PD 
was confirmed in primates and human 
specimens postmortem, with good cor-
relation between the density of SNpc 
neuromelanin that contained neurons 
and neuromelanin-related MR imaging 
signal intensity (12,13).
Previous studies also demonstrated 
the potential of neuromelanin-related 
SNpc signal intensity loss to index 
disease progression by showing Hoehn 
and Yahr stage-dependent changes 
(14–16). It is unclear whether and how 
closely neuromelanin-related SNpc sig-
nal intensity changes correlate to the 
Unified Parkinson’s Disease Rating 
Scale (UPDRS) scores as a more accu-
rate estimator of disease severity. How 
well neuromelanin MR imaging reflects 
Parkinson disease (PD) is charac-terized by a depletion of catechol-aminergic neurons in brainstem 
gray matter nuclei, such as the substan-
tia nigra pars compacta (SNpc), the 
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Advances in Knowledge
 n Neuromelanin-weighted MR im-
aging sequences with additional 
magnetization-transfer pulses are 
sensitive to Parkinson disease 
(PD)–induced depigmentation of 
the substantia nigra pars com-
pacta (SNpc) (volume in control 
subjects, 112.8 mm3 6 46.1; 
volume in patients with PD, 52.8 
mm3 6 29.4; P , .001) and locus 
coeruleus (LC) (volume in con-
trol subjects, 16.7 mm3 6 9.1; 
volume in patients with PD, 11.7 
mm3 6 6.2; P , .05) but not to 
neuronal loss in the ventral teg-
mental area (VTA) (volume in 
control subjects, 1.3 mm3 6 1.6; 
volume in patients with PD, 1.5 
6 2.2 [not significant]).
 n Variations in MR sequences and 
imaging unit platforms can be 
corrected by using sequence-spe-
cific signal intensity thresholds, 
thereby enabling between-site 
standardized volumetric analysis.
 n The most severe PD-induced 
signal intensity volume loss is 
found in the posterior SNpc 
(median, 83%; range, 34%–
100%), which correlates well with 
findings in previous histopatho-
logic studies and shows one of the 
best receiver operating character-
istic (ROC) values (area under 
the ROC curve, 0.92 6 0.03; P , 
.001) to distinguish patients with 
PD from healthy control subjects.
 n There is a significant inverse cor-
relation of the Unified Parkinson’s 
Disease Rating Scale score (a clin-
ical measure of disease severity) 
with the signal intensity volume of 
the anterior (r2 = 0.25, P , .05), 
posterior (r2 = 0.22, P , .05), 
and whole (r2 = 0.28, P , .05) 
SNpc but not that of the LC or 
the VTA (SNpc volumes corrected 
for age and cerebral volume).
disease progression and which subre-
gions are most suited to index disease 
severity also remain unknown.
Additionally, there is lack of stan-
dardization, with studies to date vary-
ing in acquisition and analysis proto-
cols; this significantly limits the wider 
clinical use of neuromelanin MR imag-
ing. To the best of our knowledge, there 
are currently no investigators studying 
and controlling for the effects of dif-
ferent imaging unit platforms and se-
quences on neuromelanin-related signal 
intensity. Being able to compare results 
independent of different imaging unit 
platforms or sequences is, however, im-
perative if this technique is to be used 
clinically or in multicenter trials.
The purpose of this study was to 
investigate the pattern of neuromelanin 
signal intensity loss within the SNpc, 
LC, and VTA in PD. The specific aims 
were (a) to study regional MR-quan-
tifiable depigmentation in association 
with PD severity and (b) to investigate 
whether imaging- and platform-depen-
dent signal intensity variations can be 
normalized.
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in neuroradiology with 8 years of expe-
rience in movement disorder imaging 
research) (14,18,19). Suprathreshold 
hyperintense volumes were assessed 
on three adjacent sections in the whole 
SNpc, VTA, and LC. In addition, the 
SNpc was geometrically divided into 
anterior and posterior halves by using 
manually placed regions of interest (an-
terior and posterior SNpc, performed by 
S.T.S.). Region of interest placement and 
signal intensity distribution were deter-
mined by using image analysis software 
(Jim version 7.0, Xinapse Systems, Col-
chester, United Kingdom; www.xinapse.
com). For more details, see Figures E1–
E6 (online). Backgrounds were chosen 
as midbrain tegmentum and cerebral pe-
duncles for the SNpc and VTA, respec-
tively, and the pons for the LC. We aver-
aged the signal intensity obtained from 
the background regions of interest for 
calculation of the mean background sig-
nal intensity and expressed background 
noise as the standard deviation (SD) of 
the background signal intensity.
We determined an adjustment factor 
for the threshold to define neuromelanin-
containing voxels across acquisition pro-
tocols and imaging units. We achieved 
this by identifying a reference protocol 
out of the three neuromelanin-sensitive 
MR imaging protocols that best matched 
the normative volumes from a recent 
previously (14). The current study ex-
pands on the prior study by introducing a 
new algorithm to adjust for varying neu-
romelanin-sensitive sequences and imag-
ing unit platforms by introducing a new 
segmentation technique of the substantia 
nigra and by relating neuromelanin sub-
regional SNpc signal intensity changes to 
UPDRS scores.
Imaging was performed with two 3-T 
MR imaging units (Achieva, Philips Med-
ical Systems, Best, the Netherlands; and 
Discovery MR750, GE Healthcare, Mil-
waukee, Wis) with eight- and 32-chan-
nel head coils, respectively, and three 
different sequences (spectral presatura-
tion inversion-recovery acquisition with 
the Philips imaging unit, magnetization-
transfer [MT] acquisition with the Philips 
imaging unit, and MT acquisition with 
the GE Healthcare imaging unit; Table 1). 
The orientation of the axial sections was 
individually aligned parallel to a line that 
connected the splenium and genu of the 
corpus callosum. High-spatial-resolution 
anatomic images were obtained in each 
individual’s brain by using a T1-weighted 
three-dimensional magnetization-pre-
pared rapid-acquisition gradient-echo 
sequence (voxel size, 1 mm isotropic).
We modified a previously proposed 
analysis method to determine hyper-
intense neuromelanin-rich volumes 
(S.T.S., a senior clinical research fellow 
Materials and Methods
This final analysis was part of a pro-
spective multimodal MR imaging char-
acterization of the SNpc in patients 
with PD and was approved by the local 
ethics committee (North Nottingham-
shire Research Ethics Committee, United 
Kingdom, reference no. 05/Q2402/87; 
Derbyshire Research Ethics Commit-
tee, United Kingdom, reference no. 10/
H0401/35) and the research department 
of Nottingham University Hospitals NHS 
Trust. Data were collected periodically 
from March 2007 to March 2015. All par-
ticipants had to be 30 years and older, 
have undergone the Addenbrooke’s Cog-
nitive Examination test battery, and had 
to have a score higher than 80 for inclu-
sion. All participants had Mini-Mental 
State examination scores of at least 27. 
All patients included in the study had to 
fulfill the UK Brain Bank criteria for a di-
agnosis of PD and were recruited from 
movement disorders clinics at two local 
National Health Service trusts. All con-
trol subjects were recruited via spouses 
and friends and had to be free from 
movement disorder symptoms. Partic-
ipants were excluded from the study if 
there were any contraindications to MR 
imaging, such as potential intraocular 
metallic foreign bodies, intracranial 
aneurysm clips, cardiac pacemakers, 
defibrillators, or cochlear implants. Of 
112 participants enrolled, 76 participants 
were recruited into the neuromelanin 
substudy and underwent imaging with 
any of three prespecified neuromelanin-
sensitive MR imaging protocols. Six par-
ticipants had to be excluded because of 
severe movement artifacts. One patient 
was excluded because of change of diag-
nosis at follow-up (Fig 1). The final study 
analysis included 39 patients and 30 con-
trol subjects. Written informed consent 
was obtained from all participants before 
enrollment in the study after undergoing 
assessment of capacity by a neurol-
ogy consultant (N.B.). Disease severity 
was recorded by using the UPDRS and 
Hoehn and Yahr clinical rating scales for 
PD (17). Patients were assessed and un-
derwent imaging while medicated. Data 
from 17 of the 69 participants included 
in the current study have been reported 
Figure 1
Figure 1: Participant inclusion flowchart. m. = movement.
4 radiology.rsna.org n Radiology: Volume 000: Number 0—   2016
NEURORADIOLOGY: In Vivo Assessment of Brainstem Depigmentation in Parkinson Disease Schwarz et al
for Functional MRI of the Brain, or 
FMRIB, linear imaging registration tool 
(http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/
FLIRT; Appendix E1 [online]).
Statistical tests (including ROC 
analyses, linear regression, and analysis 
of variance) were performed by using 
IBM-SPSS for windows (version 21.0; 
IBM, Armonk, NY) and Microsoft Ex-
cel 2010 (Microsoft, Redmond, Wash). 
Group comparisons between patients 
and control subjects were performed 
by using univariate or multivariate 
analysis of variance with least-squares 
differences post hoc comparison or Stu-
dent t tests. Nonparametric tests were 
used for group comparisons in case 
of nonnormal distribution of the data. 
Values are given as means 6 SDs or as 
medians with interquartile ranges and 
ranges, unless stated otherwise. Signif-
icance was defined at P less than .05. 
ROC analyses and intraclass correlation 
coefficient analyses (the second mea-
surement performed by Y.X., a blinded 
investigator) were performed by using 
SPSS software (for details, see Appen-
dix E1 [online]). Partial correlation 
analysis was performed by using SPSS 
and Matlab software version 2015a 
(http://www.mathworks.com/products/
matlab; S.T.S. and Y.X.).
Results
There was no difference in age or sex 
distribution of the patients with PD and 
the control subjects (patients with PD, 
22 men [mean age, 66 years 6 7.6; age 
of the background signal intensity) in 
healthy control subjects, and for each 
sequence, we chose a multiplier that 
was used to adjust the respective con-
trol group mean to the signal intensity 
volume of the reference protocol (Fig 
2b; left solid arrow, spectral presatu-
ration inversion-recovery acquisition 
with the Philips imaging unit [2.75 SD 
+ background signal intensity]; right 
solid arrow, MT acquisition with the 
GE Healthcare imaging unit [3.57 SD 
+ background signal intensity]). This 
enabled us to establish normalized neu-
romelanin volumes. To examine the ac-
curacy of neuromelanin-weighted MR 
imaging as a diagnostic test of PD in 
comparison to control subjects, a re-
ceiver operating characteristic (ROC) 
analysis of subregional neuromelanin 
volumes was performed before and 
after protocol-specific threshold signal 
intensity adjustment.
To further adjust for variations in 
cerebral volumes, we calculated the 
total cerebral volumes (hemispheric 
and subcortical gray and white mat-
ter) by using FreeSurfer 5.3 (https://
surfer.nmr.mgh.harvard.edu/; analysis 
performed by Y.X., a postdoctoral re-
search fellow with more than 3 years of 
imaging research in PD).
To visually display the disease 
stage–dependent depigmentation in 
PD, we constructed a group-averaged 
neuromelanin map (Fig 3) by register-
ing neuromelanin images to the high-
spatial-resolution anatomic volumes by 
using “FSL FLIRT,” the Oxford Centre 
histologic study (20). We then standard-
ized the group mean SNpc volumes of 
respective healthy control subjects in the 
other two groups to the values observed 
in the reference protocol. The mean 
overall substantia nigra volume (right and 
left) in the postmortem study (eight fe-
male patients and seven male patients; 
age range, 50–91 years; mean age 6 SD, 
67.4 years 6 13.2) was reported as 187.8 
mm3 6 34.1 (20). The substantia nigra 
consists of approximately 68% pigment-
ed neurons (21), which allowed estima-
tion of a “normal” pigmented substantia 
nigra volume of 127.7 mm3 6 23.1.
By choosing a previously published 
threshold signal intensity method for 
determination of high-signal-intensity 
SNpc neurons as a reference (14), we 
found that determination of neuromela-
nin-rich volume in the control cohort 
that underwent MT acquisition with 
the Philips imaging unit yielded a group 
mean pigmented SNpc volume of 106.9 
mm3 6 47, which best matched the ex-
pected pigmented volume (Fig 2a, n = 10 
each) (20,21). Threshold signal intensity 
(THRsi) was calculated as follows:
 = + ×si mean BGTHR BG (3 SD ), 
where BGmean is the mean background 
signal intensity and SDBG is the SD of 
the background signal intensity. The 
suprathreshold signal intensity vol-
umes with the other two sequences 
were investigated by using a range of 
multipliers (one to five times the SD 
Table 1
MR Sequences Used to Assess Brainstem Neuromelanin Content of the Substantia Nigra, LC, and VTA
Sequence Participants Sequence Parameters
Spectral presaturation 
inversion-recovery 
acquisition with the 
Philips imaging unit
10 control subjects,  
12 patients with PD
T1-weighted imaging with spectral presaturation inversion-recovery pulse conferring an MT effect within the 
specific absorption rate limits (repetition time [msec]/echo time [msec], 688/9; section thickness, 2.5 mm; 
0.25-mm gap; 0.47 3 0.47 pixel resolution; four signals acquired, 21 sections; acquisition time, 12 minutes)
MT acquisition with the 
Philips imaging unit
10 control subjects,  
12 patients with PD
Modified version of the above T1-weighted sequence, replacing the spectral presaturation inversion-recovery 
pulse with a standard Philips “off-resonance” MT pulse (904/9; section thickness, 2.5 mm; 0.25-mm gap;  
0.47 3 0.47 pixel resolution; four signals acquired; 12 sections; acquisition time, 12 minutes 34 seconds)
MT acquisition with the  
GE Healthcare  
imaging unit
10 control subjects,  
15 patients with PD
T1-weighted spin-echo sequence with additional “off-resonance” MT pulse (600/10; section thickness, 2.5 mm; 
0.38 3 0.38 pixel resolution; 0.3-mm gap; three signals acquired; 12 sections; acquisition time, 9 minutes  
32 seconds)
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range, 51.8–87.1 years] and 17 women 
[mean age, 66.5 years 6 11; age range, 
41.3–82.8 years]; mean age for all 
patients with PD, 66.2 years 6 9.1; 
Figure 2
Figure 2: Adjustment to account for MR sequence–dependent  
neuromelanin-related signal intensity. (a) Bar graph shows 
threshold (given as a multiplier of SD, x-axis) and sequence-
dependent brainstem neuromelanin volume (y-axis) in healthy 
control subjects before (first three bars) and after (last three 
bars) threshold signal intensity adjustment. (b) Graph indicates 
that by using 3 SDs above mean background signal intensity for 
the group that underwent MT acquisition with the Philips (PHIL) 
imaging unit as the reference (striped arrow), the resultant 
volume allows derivation of the corresponding multipliers for the 
other sequences (solid arrows). GE = GE Healthcare, SE = stan-
dard error, SN = substantia nigra, SPIR = spectral presaturation 
inversion recovery.
control subjects, 17 men [mean age, 
63.6 years 6 6.6; age range, 52.2–75.6 
years] and 13 women [mean age, 67.7 
years 6 7; age range, 59–81.7 years]; 
mean age for all control subjects, 65.4 
years 6 7; for further breakdown of 
individual groups, see Appendix E1 
[online]). Patients with PD had mild to 
moderate disease severity, with UPDRS 
scores ranging from 2 to 60 and Hoehn 
and Yahr stages ranging from 1 to 3 (n 
= 39; median UPDRS score, 19; me-
dian Hoehn and Yahr score, 1.5). The 
disease duration ranged from 0.1 to 15 
years (median, 2 years).
Protocol Dependence and Adjustment 
Results
The absolute neuromelanin-related sig-
nal intensity volume of the brainstem nu-
clei (sum of substantia nigra, VTA, and 
LC signal intensities) was dependent on 
the MR imaging sequence used in the 
three different control groups. The larg-
est overall hyperintense volume at the 
fixed threshold (mean + 3 SDs of back-
ground signal intensity) was observed in 
the control group that underwent MT 
acquisition with the GE Healthcare im-
aging unit (233 mm3 6 73), followed by 
the group that underwent MT imaging 
with the Philips imaging unit (129 mm3 
6 46); we found the smallest volume in 
the group that underwent spectral pre-
saturation inversion-recovery acquisition 
with the Philips imaging unit (83 mm3 6 
19; n = 10 in each group; F(2,29) = 22.7; 
P , .001). There was also sequence de-
pendence of the neuromelanin-related 
volumes of the individual nuclei of an-
terior and posterior SNpc, LC, and VTA 
(multivariate analysis, Wilks l F(10,46) = 
4.6; P , .001; with post hoc analysis, 
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markers of PD (Fig 4). The area under 
the ROC curve (AUC) for the normal-
ized (threshold-adjusted) posterior and 
whole SNpc neuromelanin-rich volumes 
demonstrated the best distinction be-
tween patients with PD and control 
subjects (posterior SNpc, adjusted AUC 
6 standard error of 0.92 6 0.03 [P , 
.001], nonadjusted AUC of 0.82 6 0.05 
[P , .001], and z = 22.72 [P = .006] 
for adjusted AUC vs nonadjusted AUC 
[22]; whole SNpc, adjusted AUC of 0.88 
6 0.04 [P , .001], nonadjusted AUC of 
0.76 6 0.06 [P , .001], and z = 22.56 
[P = .01] for adjusted AUC vs nonad-
justed AUC). Measurements in the an-
terior SNpc and the LC demonstrated 
good to moderate AUC values when 
values adjusted for threshold signal in-
tensity were used (AUC 6 standard er-
ror, 0.82 6 0.05 [P , .001] and 0.67 
6 0.07 [P = .02], respectively) with 
the LC region). There was no significant 
correlation of cerebral volumes with any 
of the brainstem nuclei neuromelanin 
volumes in the healthy control group 
(lowest P value, P = .48 in the LC re-
gion) or the PD group (lowest P value, 
P = .30 in the whole SNpc region). The 
intraclass and interclass correlation co-
efficients for intrarater and interrater 
concordance were very high, with cor-
relation coefficients of 0.99 (95% con-
fidence interval [CI]: 0.97, 0.99) and 
0.94 (95% CI: 0.90, 0.97; all P , .001), 
respectively.
Diagnostic Performance of Normalized 
and Nonnormalized Regional 
Neuromelanin Volume
The sequence-specific normalization 
procedure significantly improved the 
diagnostic test performance of using 
regional neuromelanin measures as 
all subregions were significantly differ-
ent; see Fig 2a). After threshold adjust-
ment as described earlier, there was no 
significant difference in hyperintense 
volumes of the brainstem nuclei nor in 
the distribution of hyperintense volumes 
within the anterior and posterior SNpc, 
VTA, and LC (F(10,46) = 0.7; P = .41; with 
post hoc analysis, there was no signif-
icant difference between subregions; 
lowest P value, P = .18 in the LC region; 
Fig 2a). By using normalized signal in-
tensity volumes, we found a mild neg-
ative correlation of the signal intensity 
volume of the anterior SNpc with age 
in all control subjects (r2 = 0.14; F1,29 = 
4.5; P = .04) but not in the PD group 
(anterior SNpc, P = .94) or in the other 
brainstem regions (for control subjects 
the lowest P value was P = .08 in the 
posterior SNpc region; for patients with 
PD the lowest P value was P = .22 in 
Figure 3
Figure 3: Left images show examples of consecutive brainstem neuromelanin-weighted axial MR images and superimposed 
suprathreshold neuromelanin-rich voxels in, A, a 63.7-year-old female control subject, B, a 64.3-year-old male patient with 
mild PD and a UPDRS score of 19, and, C, a 70.8-year-old male patient with moderate PD and a UPDRS score of 47. Right im-
ages represent group average maps of concatenated nigral neuromelanin-rich voxels projected on a T1 atlas image for control 
subjects (top), patients with mild PD (UPDRS score , 20, middle), and patients with moderate PD (UPDRS score  20, bottom).
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neuromelanin-related volumes of the 
anterior, posterior, and whole SNpc 
and the LC (Table 2). The PD-relat-
ed neuromelanin signal intensity loss 
showed a regional pattern, with the 
most pronounced median signal inten-
sity loss of 83% in the posterior SNpc 
(interquartile range, 56%–92%; range, 
34%–100%). We found a median re-
duction of 56% in neuromelanin-rich 
volumes in the whole SNpc (interquar-
tile range, 42%–68%; range, 210% to 
97%), a median reduction of 49% in 
the anterior SNpc (interquartile range, 
23%–63%; range, 230% to 99%), and 
a median reduction of 37% in the LC 
(interquartile range, 0%–54%; range, 
279% to 77%) in our investigated pa-
tient group, with mild to moderately se-
vere PD (Figs 3, 5). The hyperintensity 
within the VTA region was small, with 
no significant group difference (thresh-
old signal intensity adjusted for control 
subjects, 1.3 mm3 6 1.6; threshold sig-
nal intensity adjusted for PD, 1.5 mm3 
6 2.2; P = .61).
Neuromelanin Loss and Disease Severity
There was a borderline nonsignificant 
correlation of Hoehn and Yahr score 
with normalized neuromelanin volume 
of the whole SNpc (r = 20.31, P = .051), 
sensitivity of 89.7% (35 of 39 patients; 
95% CI: 80.1%, 99.2%) and a specific-
ity of 83.3% (25 of 30 control subjects; 
95% CI: 70%, 96.6%). When using the 
whole SNpc value for classification, it 
was used to differentiate patients with 
PD and control subjects with a sensi-
tivity of 82.0% (32 of 39 patients, 95% 
CI: 70%, 94.1%) and a specificity of 
83.3% (25 of 30 control subjects; 95% 
CI: 70%, 96.6%).
Pattern of Neuromelanin in Healthy Aging 
and PD
In healthy control subjects, most of 
the neuromelanin-related signal inten-
sity in the SNpc was located anteriorly 
(mean 6 SD, 78% 6 10 vs 22% 6 9 
posteriorly; P , .001). The relative 
distribution of anterior and posterior 
SNpc volumes was independent of the 
MR imaging sequence (F(2,29) = 0.89, P 
= .43). In patients with PD, the relative 
signal intensity content of the posterior 
SNpc was smaller than that in control 
subjects (patients with PD, 13% 6 11; 
median, 11%; interquartile range, 4%–
17%; range, 0%–60%; Mann Whitney 
U test for patients vs control subjects, 
P , .001). In comparison to control 
subjects, patients with PD showed a 
significant reduction in normalized 
poorer performance when using values 
not adjusted for threshold signal inten-
sity (AUC 6 standard error for anterior 
SNpc, 0.72 6 0.06; LC, 0.64 6 0.7; ad-
justed vs nonadjusted AUC, z = 22.1 [P = 
.02] and z = 0.38 [P = .7], respectively). 
VTA volumes did not allow separation of 
the groups (adjusted AUC 6 standard 
error, 0.51 6 0.07; nonadjusted AUC 6 
standard error, 0.48 6 0.07).
Comparing the diagnostic test per-
formances of the adjusted individual 
SNpc regions and the LC as disease 
classifiers demonstrated that the high-
est AUC value of the posterior SNpc 
was not significantly different from that 
of the whole SNpc (z = 1.03, P = .30). 
There was, however, a significant differ-
ence when comparing the AUC of the 
posterior and whole SNpc with the AUC 
of the anterior SNpc and LC (lowest z 
value, z = 2.1; P = .04).
The optimal cutoff value of poste-
rior and whole SNpc volumes to differ-
entiate patients with PD and control 
subjects with the highest sensitivity and 
specificity was determined to be 10.72 
mm3 for posterior SNpc and 72.98 
mm3 for whole SNpc. When using the 
posterior SNpc value for classification, 
it was used to differentiate patients 
with PD and control subjects with a 
Figure 4
Figure 4: ROC analysis of pigmented volumes of midbrain nuclei was conducted to diagnose PD, A, before and, B, after normalization 
by using sequence-specific threshold adjustments. Diagonal segments are produced by ties. adj. = adjusted, aSNpc = anterior SNpc, 
pSNpc = posterior SNpc, THRsi = threshold signal intensity, wSNpc = whole SNpc.
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precision of neuromelanin MR imag-
ing techniques in tracking the volume 
of pigmented brainstem nuclei can be 
improved further.
Even after controlling for cerebral 
volume and age, we found significant 
correlation of neuromelanin volumes in 
both anterior and posterior SNpc with 
disease severity, as measured with the 
UPDRS. This is well in line with pre-
vious observations of increased neu-
romelanin loss with more advanced 
disease, with Hoehn and Yahr stages 
a less accurate measure of disease se-
verity (11,14,15,26). In contrast to our 
finding, a recent study in which an au-
tomated SNpc segmentation algorithm 
was used did not yield a correlation 
of the substantia nigra volume with 
the motor UPDRS (27), which might 
relate to technical differences. There 
was no correlation of LC volume with 
measures of disease severity, which is 
in line with postmortem studies that 
demonstrated LC cell loss indepen-
dent of disease duration (28–30). The 
absolute degree of postmortem LC 
cell loss found is relatively more (ap-
proximately 60% more) (28) than the 
LC signal intensity loss we or other 
groups observed (10,27). A potential 
different protocols and varying 3-T MR 
imaging setups, and it holds promise as 
a useful biomarker for clinicians and in 
clinical trials.
Use of a previously unpublished 
normalization algorithm yielded pig-
mented SNpc volumes in healthy con-
trol subjects that closely matched true 
in vitro SNpc volume measurements 
from postmortem studies. We achieved 
improved diagnostic accuracy not only 
when compared with unadjusted volu-
metry but also when compared with 
single-center studies (11,23,24). As a 
further quantitative validation of our 
neuromelanin analysis, we note that the 
preferential volume loss in the region 
of the posterior substantia nigra com-
pares well to histologic findings of PD-
induced cell loss of in the lateral ven-
tral tier described by Fearnly and Lees 
(25). However, despite the most signif-
icant signal intensity loss and the best 
ROC curves of the posterior and whole 
SNpc measures, there was an overlap 
of volumes in patients with PD and con-
trol subjects. The number of pigmented 
brainstem neurons and the SNpc vol-
umes vary greatly, even in a healthy 
population within a certain age range 
(20). The overlap observed may be a 
reflection of true interindividual dif-
ferences in nigral pigmented volumes. 
However, the relative variance of SNpc 
volumes in control subjects observed in 
the present study by using threshold-
adjusted neuromelanin MR imaging is 
more than double the relative variance 
in control subjects in histologic studies. 
Therefore, it is conceivable that the 
and there was no significant correlation 
with the LC (P = .15, Pearson corre-
lation). We found a significant mild to 
moderate negative correlation of UP-
DRS score with normalized neuromela-
nin volume, controlled for cerebral vol-
ume and age in the anterior SNpc (r = 
20.48, P = .003), posterior SNpc (r = 
20.45, P = .007), and whole SNpc (r = 
20.50, P = .002; Figs 3, 6) but not in 
the LC or VTA (P = .24 and .44, respec-
tively; Pearson correlation). There was 
no significant correlation of disease du-
ration with any of the brainstem nuclei 
neuromelanin signal intensity when cor-
rected for age (lowest P value, P = .16).
Discussion
This current study confirms that neu-
romelanin-weighted MR imaging is 
sensitive for PD-induced brainstem de-
pigmentation. We describe preferential 
neuromelanin-rich volume loss in the 
posterior SNpc, followed by the ante-
rior SNpc and the LC. Assessment for 
neuromelanin-related signal intensity 
loss in the whole or posterior SNpc 
yielded the best classification charac-
teristics to distinguish patients with PD 
and control subjects. SNpc depigmenta-
tion was mild to moderately correlated 
with disease severity in a patient cohort 
with mild to moderate disease. More-
over, we demonstrated how to effec-
tively adjust for protocol-specific neu-
romelanin signal intensity differences. 
Neuromelanin MR imaging has poten-
tial as a tool for monitoring PD sever-
ity–related changes, even when using 
Figure 5
Figure 5: Box and whisker plot illustrates the  
region-specific depigmentation (normalized neuro-
melanin volume loss) in patients with PD. The 
volume reduction in the posterior SNpc (pSNpc) is 
larger than that in the other pigmented brainstem 
regions. aSNpc = anterior SNpc. ∗ 5 P , .05, 
∗∗∗ 5 P , .001, according to the Wilcoxon rank 
sum test.
Table 2
Normalized Neuromelanin-related Volumes of Brainstem Nuclei in Patients with PD 
and Control Subjects
Nuclei Control Subjects (n = 30) Patients with PD (n = 39) P Value*
Anterior SNpc (mm3) 87.9 6 37.7 (80.2) [31.5–160.4] 47.3 6 26.6 (44.1) [1.2–117.3] ,.001
Posterior SNpc (mm3) 24.8 6 16 (23.6) [2–72.8] 5.5 6 4.51 (4.9) [0–19] ,.001
Whole SNpc (mm3) 112.8 6 46.1 (106.9) [44.9–204.1] 52.8 6 29.4 (49.8) [3–127] ,.001
LC (mm3) 16.7 6 9.1 (14.4) [4.5–38.9] 11.7 6 6.2 (10.3) [1.6–27.9] .02
VTA (mm3) 1.3 6 1.6 (0.7) [0–5.7] 1.5 6 2.2 (0.61) [0–9.3] .88
Note.—Data are means 6 SDs, unless indicated otherwise. Numbers in parentheses are median values. Numbers in brackets 
are ranges.
* According to the Mann-Whitney U test.
Radiology: Volume 000: Number 0—   2016 n radiology.rsna.org 9
NEURORADIOLOGY: In Vivo Assessment of Brainstem Depigmentation in Parkinson Disease Schwarz et al
relevant relationships. N.B. disclosed no rele-
vant relationships. D.P.A. disclosed no relevant 
relationships.
References
 1. Greenfield JG, Bosanquet FD. The brain-
stem lesions in Parkinsonism. J Neurol Neu-
rosurg Psychiatry 1953;16(4):213–226.
 2. Bazelon M, Fenichel GM, Randall J. Studies 
on neuromelanin. I. A melanin system in the 
human adult brainstem. Neurology 1967; 
17(5):512–519.
 3. Zucca FA, Bellei C, Giannelli S, et al. Neu-
romelanin and iron in human locus coeruleus 
and substantia nigra during aging: conse-
quences for neuronal vulnerability. J Neural 
Transm (Vienna) 2006;113(6):757–767.
 4. Halliday GM, Fedorow H, Rickert CH, Ger-
lach M, Riederer P, Double KL. Evidence 
for specific phases in the development of 
human neuromelanin. J Neural Transm (Vi-
enna) 2006;113(6):721–728.
 5. Lees AJ, Selikhova M, Andrade LA, Duyck-
aerts C. The black stuff and Konstan-
tin Nikolaevich Tretiakoff. Mov Disord 
2008;23(6):777–783.
 6. Uhl GR, Hedreen JC, Price DL. Parkinson’s 
disease: loss of neurons from the ventral teg-
mental area contralateral to therapeutic surgi-
cal lesions. Neurology 1985;35(8):1215–1218.
 7. Gibb WR, Lees AJ. Anatomy, pigmentation, 
ventral and dorsal subpopulations of the 
substantia nigra, and differential cell death 
in Parkinson’s disease. J Neurol Neurosurg 
Psychiatry 1991;54(5):388–396.
neuromelanin volumetry as a progres-
sion marker, but longitudinal studies 
that include large patient cohorts are 
needed to assess the performance of 
neuromelanin MR imaging to directly 
track disease progression.
In conclusion, neuromelanin-weight-
ed MR imaging sequences performed at 
3 T are sensitive for PD-induced depig-
mentation of the SNpc, with excellent 
diagnostic accuracy for posterior and 
whole SNpc (AUC, 0.92 and 0.88, re-
spectively) and may offer a progression 
marker in mild to moderate PD. The 
proposed threshold adaptation for vol-
umetric analysis allows correction for 
variations in acquisition protocols as 
a critical step toward advancing neu-
romelanin MR imaging techniques for 
clinical use. Longitudinal studies are 
now warranted to confirm the potential 
of neuromelanin-weighted MR imaging 
as a marker of disease progression for 
multicenter trials.
Acknowledgments: We thank the PD research 
study nurses of the Derby Hospitals NHS Foun-
dation Trust for support with participant recruit-
ment and assessment, and we thank all study 
volunteers for their participation. We acknowl-
edge Penny Gowland, PhD, for useful discus-
sions and cofunding of the study.
Disclosures of Conflicts of Interest: S.T.S. dis-
closed no relevant relationships. Y.X. disclosed 
no relevant relationships. P.T. disclosed no 
explanation is the limited resolution of 
MR imaging for accurate quantification 
of signal intensity in this small nucleus. 
This and the lower density of pigment-
ed dopaminergic cells in the VTA (31) 
will explain the lack of observed VTA 
changes. A further possible reason for 
reduced sensitivity in the detection of 
PD-induced LC and VTA depigmenta-
tion may come from the fact that we 
optimized the threshold for definition 
of pigmented SNpc.
A limitation of this study is the 
small sample size of the cohorts in-
vestigated. Also, ideally, a single con-
trol group in which the three differ-
ent sequences are used to assess MR 
imaging sequence–dependent signal 
intensity alterations should be inves-
tigated; however, this is often not a 
feasible option for multicenter stud-
ies. Therefore, our approach of us-
ing an age- and sex-matched control 
group to adjust for sequence-inherent 
neuromelanin contrast and noise dif-
ferences is a pragmatic and relevant 
approach that allows comparison and 
combination of data sets recorded 
with different sequences and varying 
platforms on limited–sample size nor-
mative data sets. The observed mild 
to moderate correlation with disease 
severity highlights the potential of 
Figure 6
Figure 6: Scatterplots demonstrate the variability of anterior SNpc (aSNpc) and posterior SNpc (pSNpc) volume in relation to UPDRS score. The substantia nigra 
volumes are corrected for age and cerebral volume. The dotted lines represent the computed borders of the variability of the mean anterior SNpc and posterior SNpc 
volume by 2 SDs (95% CI) in relation to UPDRS score.
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